Ефективність різних схем ерадикаційної терапії в дітей, хворих на хелікобактер-асоційовану патологію верхніх відділів шлунково-кишкового тракту
DOI :
https://doi.org/10.15587/2313-8416.2016.61176Mots-clés :
діти, Helicobacter pylori, патологія верхніх відділів шлунково-кишкового тракту, лікуванняRésumé
Встановлено, що найбільш ефективною схемою антихелікобактерної терапії в дітей із патологією верхніх відділів шлунково-кишкового тракту є застосування інгібітора протонової помпи, кларитроміцину та ніфурателю впродовж 10 днів (ерадикація 90 %, зниження відносного ризику рецидиву становить 0,44 (ДІ:0,17–5,45), а кількість хворих, що необхідно пролікувати для досягнення одного позитивного результату – 3,3 (ДІ:1,13–12,28)
Références
Zimmerman, J. S. (2015). Gastrojenterologija. Rukovodstvo [Gastroenterology. Manual]. Moscow: HЕOTAR-Medik, 816.
Bogdanov, D. J., Vashchenko, I. I., Surkacheva, O. A., Astapenkov, Y. I. (2011). Bolezny orhanov pyshchevarenyya pry khelykobakteryoze [Diseases of the digestive system with Helicobacter pylori infection]. Moscow: OOO "Medical News Agency", 224.
Yvashkyn, V. T., Bohdanov, D. Yu., Lapyna, T. L. (2013). Gastrojenterologija. Klinicheskoe rukovodstvo [Gastroenterology. Manual]. Moscow: HEOTAR, 208.
Malfertheiner, P., Mégraud, F., OʼMorain, C., Bell, D., Porro, B. G., Deltenre, M. et. al (1997). Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. European Journal of Gastroenterology & Hepatology, 9 (1), 1–2. doi: 10.1097/00042737-199701000-00002
Malfertheiner, P., Megraud, F., O’Morain, C., Hungin, A. P. S., Jones, R., Axon, A. et. al (2002). Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Alimentary Pharmacology and Therapeutics, 16 (2), 167–180. doi: 10.1046/j.1365-2036.2002.01169.x
Malfertheiner, P., Megraud, F., O’Morain, C., Bazzoli, F., El-Omar, E., Graham, D. et. al (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 56 (6), 772–781. doi: 10.1136/gut.2006.101634
Malfertheiner, P., Megraud, F., O’Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F. et. al (2012). Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut, 61 (5), 646–664. doi: 10.1136/gutjnl-2012-302084
Standartyi diagnostiki i lecheniya kislotozavisimyih i assotsiirovannyih s Helicobacter pylori zabolevaniy (chetvertoe Moskovskoe soglashenie) [Diagnostic standards and treatment of acid and Helicobacter pylori-associated diseases (fourth Moscow Agreement)] (2010). Guidelines Moscow City Department of Health, № 37. Moscow: CNIIG, 12.
Leanza, A. G., Matteo, M. J., Crespo, O., Antelo, P., Olmos, J., Catalano, M. (2004). Genetic characterisation of Helicobacter pylori isolates from an Argentinean adult population based on cag pathogenicity island right-end motifs, lspA-glmM polymorphism and iceA and vacA genotypes. Clinical Microbiology and Infection, 10 (9), 811–819. doi: 10.1111/j.1198-743x.2004.00940.x
Kato, S., Fujimura, S. (2010). Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatrics International, 52 (2), 187–190. doi: 10.1111/j.1442-200x.2009.02915.x
Boyanova, L. (2009). Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. Journal of Medical Microbiology, 58 (7), 930–935. doi: 10.1099/jmm.0.009993-0
Yuan, Y., Ford, A. C., Khan, K. J., Gisbert, J. P., Forman, D., Leontiadis, G. I. et. al (2013). Optimum duration of regimens for Helicobacter pylori eradication. John Wiley & Sons. doi: 10.1002/14651858.cd008337.pub2
Machado, R. S., da Silva, M. R., Viriato, A. (2008). Furazolidone, tetracycline and omeprazole: a low-cost alternative for Helicobacter pylori eradication in children. Jornal de Pediatria, 84 (2), 160–165. doi: 10.2223/jped.1772
Filipec Kanizaj, T., Katicic, M., Skurla, B., Ticak, M., Plecko, V., Kalenic, S. (2009). Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens. Helicobacter, 14 (1), 29–35. doi: 10.1111/j.1523-5378.2009.00656.x
Alvarez, A., Moncayo, J. I., Santacruz, J. J., Santacoloma, M., Corredor, L. F., Reinosa, E. (2009). Antimicrobial Susceptibility and Mutations Involved in Clarithromycin Resistance in Helicobacter pylori Isolates from Patients in the Western Central Region of Colombia. Antimicrobial Agents and Chemotherapy, 53 (9), 4022–4024. doi: 10.1128/aac.00145-09
Bago, J., Majstorović, K., Belošić-Halle, Ž., Kućišec, N., Bakula, V., Tomić, M. et. al (2010). Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Annals of Clinical Microbiology and Antimicrobials, 9 (1), 13. doi: 10.1186/1476-0711-9-13
Basu, P. P., Rayapudi, K., Pacana, T., Shah, N. J., Krishnaswamy, N., Flynn, M. (2011). A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pylori. The American Journal of Gastroenterology, 106 (11), 1970–1975. doi: 10.1038/ajg.2011.306
Burkova, V. V. (2012). Ispolzovanie nifuratelya v eradikatsionnoy sheme pri lechenii helikobakterioza v detey [Using nifuratel eradication scheme in the treatment of children in helikobakter]. Medicine, 2, 45–47.
Drumm, B., Koletzko, S., Oderda, G. (2000). Helicobacter pylori Infection in Children: A Consensus Statement. Journal of Pediatric Gastroenterology and Nutrition, 30 (2), 207–213. doi: 10.1097/00005176-200002000-00020
Protokoly diagnostyky ta likuvannja zahvorjuvan' organiv travlennja u ditej (2010). Ministerstvo osvity i nauky Ukrai'ny; Nakaz MOZ Ukrai'ny vid 26.05.2010 roku № 438. Kyiv. Available at: http://www.moz.gov.ua/ua/portal/dn_20100526_438.html
Dore, M. P., Farina, V., Cuccu, M., Mameli, L., Massarelli, G., Graham, D. Y. (2011). Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days. Helicobacter, 16 (4), 295–300. doi: 10.1111/j.1523-5378.2011.00857.x
Fujioka, T., Aoyama, N., Sakai, K., Miwa, Y., Kudo, M., Kawashima, J. et. al (2011). A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. Journal of Gastroenterology, 47 (3), 276–283. doi: 10.1007/s00535-011-0487-6
Nakajima, S., Inoue, H., Inoue, T., Maruoka, Y. (2012). Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. Journal of Gastroenterology and Hepatology, 27, 108–111. doi: 10.1111/j.1440-1746.2012.07069.x
Kornienko, E. A., Parolova, N. I. (2006). Antibiotikorezistentnost Helicobacter pylori u detey i vyibor terapii [Antibiotic resistance of Helicobacter pylori in children and the choice of therapy]. Questions modern pediatry, 5, 5.
Marais, A., Bilardi, C., Cantet, F., Mendz, G. L., Mégraud, F. (2003). Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Research in Microbiology, 154 (2), 137–144. doi: 10.1016/s0923-2508(03)00030-5
Mégraud, F. (2002). Helicobacter pylori and macrolides. Macrolide Antibiotics, 243–260. doi: 10.1007/978-3-0348-8105-0_15
Mendz, G. (2002). Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends in Microbiology, 10 (8), 370–375. doi: 10.1016/s0966-842x(02)02405-8
Shiota, S., Murakawi, K., Suzuki, R., Fujioka, T., Yamaoka, Y. (2013). Helicobacter pylori infection in Japan . Expert Review of Gastroenterology & Hepatology, 7 (1), 35–40. doi: 10.1586/egh.12.67
Téléchargements
Publié-e
Numéro
Rubrique
Licence
(c) Tous droits réservés Таміла Василівна Сорокман, Сніжана Василівна Сокольник, Олександра-Марія Василівна Попелюк, Олена Вікторівна Макарова, Леонід Володимирович Швигар 2016
Cette œuvre est sous licence Creative Commons Attribution 4.0 International.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
